ReviewFrontiers in immunology2026
Recent advances in tumor-activated prodrug nanoparticles for cancer immunotherapy.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Numerous therapeutic agents have been demonstrated to initiate antitumor immune responses, thereby driving significant progress in cancer immunotherapy. However, clinical translation is severely limited by persistent challenges, including systemic toxicity, the immunosuppressive tumor microenvironment (TME), and low nanoparticle delivery efficiency. Tumor-activated prodrug nanoparticles (PDNPs) integrate prodrug chemistry with nanoscale delivery, enabling localized drug activation in response to tumor microenvironmental cues or exogenous stimuli. Therapeutic specificity is improved and off-target toxicity is mitigated by this strategy, providing a promising platform for safe and effective drug delivery. Consequently, these systems have attracted extensive research attention. In this review, the design strategies, release mechanisms, and immunotherapeutic applications of TME-responsive and exogenous stimulus-responsive PDNPs are systematically detailed, together with active-targeting and hybrid strategies that further improve tumor-selective delivery and activation. Beyond serving as delivery vehicles for immunomodulators, these PDNPs are utilized in synergy with chemotherapy, photothermal/photodynamic therapy, and sonodynamic therapy to trigger immunogenic cell death. Furthermore, dendritic cell maturation and T-cell infiltration are promoted, thereby remodeling the immune microenvironment, particularly when administered in combination with immune checkpoint inhibitors. Finally, the key challenges and considerations for the clinical translation of tumor-activated PDNPs are highlighted, with the aim of guiding further research progress.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.